

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/557</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/20881</b> <b>(43) International Publication Date:</b> 22 May 1998 (22.05.98)
<b>(21) International Application Number:</b> PCT/US97/20856 <b>(22) International Filing Date:</b> 7 November 1997 (07.11.97)  <b>(30) Priority Data:</b> 60/030,506 12 November 1996 (12.11.96) US  <b>(71) Applicant (for all designated States except US):</b> ALCON LABORATORIES, INC [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SALLEE, Verney, L. [US/US]; 304 Diamond Lane, Burleson, TX 76028 (US). HELLBERG, Mark, R. [US/US]; 5211 Overridge Drive, Arlington, TX 76017 (US). KLIMKO, Peter, G. [US/US]; 2115 Pembroke Drive, Fort Worth, TX 76110 (US).  <b>(74) Agent:</b> COPELAND, Barry, L.; Alcon Laboratories, Inc., Patent Dept., Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		<b>(81) Designated States:</b> AU, CA, CN, JP, KR, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> 15-KETAL PROSTAGLANDINS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION  <b>(57) Abstract</b>  Methods and compositions for the treatment of glaucoma and ocular hypertension with 15-ketal prostaglandins are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**15-KETAL PROSTAGLANDINS FOR THE  
TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION**

**Background of the Invention**

The present invention relates to novel compounds and methods for the treatment of glaucoma and ocular hypertension. In particular, the present invention relates to the use of certain 15-ketal analogs of F series prostaglandins to treat glaucoma and ocular hypertension.

Glaucoma is a progressive disease which leads to optic nerve damage and, ultimately, total loss of vision. The causes of this disease have been the subject of extensive studies for many years, but are still not fully understood. The principal symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to excess aqueous humor in the anterior chamber of the eye.

The causes of aqueous humor accumulation in the anterior chamber are not fully understood. It is known that elevated intraocular pressure ("IOP") can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye, such as beta-blockers and carbonic anhydrase inhibitors, or increase the outflow of aqueous humor from the eye, such as miotics and sympathomimetics.


Most types of drugs conventionally used to treat glaucoma have potentially serious side effects. Miotics such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compliance or to termination of therapy. Systemically administered carbonic anhydrase inhibitors can also cause serious side effects, such as nausea, dyspepsia, fatigue, and metabolic acidosis, which side effects can affect patient compliance and/or necessitate the termination of treatment. Moreover,

some beta-blockers have increasingly become associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue. Sympathomimetics, on the other hand, may cause tachycardia, arrhythmia and hypertension. Recently, certain prostaglandins and prostaglandin derivatives have been described in the art as being useful in reducing intraocular pressure. Typically, however, prostaglandin therapy for the treatment of elevated intraocular pressure is attended by undesirable side-effects, such as irritation and hyperemia of varying severity and duration. There is therefore a continuing need for therapies which control the elevated intraocular pressure associated with glaucoma.

10

Prostaglandins are metabolite derivatives of arachidonic acid. Arachidonic acid in the body is converted to prostaglandin  $G_2$ , which is subsequently converted to prostaglandin  $H_2$ . Other naturally occurring prostaglandins are derivatives of prostaglandin  $H_2$ . A number of different types of prostaglandins are known in the art including A, B, C, D, E, F, G, I and J-Series prostaglandins (EP 0 561 073 A1). Of interest in the present invention are compounds which are believed to exhibit similar IOP lowering mechanisms to those exhibited by  $PGF_{2\alpha}$ , an F-series prostaglandin of the following formula:

20



25

The relationship of  $PGF_{2\alpha}$  receptor activation and IOP lowering effects is not well understood. It is believed that  $PGF_{2\alpha}$  receptor activation leads to increased outflow of aqueous humor. Regardless of mechanism,  $PGF_{2\alpha}$  and certain of its analogs have been shown to lower IOP (Giuffre, *The Effects of Prostaglandin  $F_{2\alpha}$  the Human Eye*, Graefe's Archive Ophthalmology, volume 222, pages 139-141 (1985); and Kerstetter et al., *Prostaglandin  $F_{2\alpha}$ -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow*, American Journal of Ophthalmology, volume 105, pages 30-34

(1988)). Thus, it has been of interest in the field to develop synthetic  $\text{PGF}_{2\alpha}$  analogs with IOP lowering efficacy.

Synthetic  $\text{PGF}_{2\alpha}$ -type analogs have been pursued in the art (Graefe's Archive  
5 Ophthalmology, volume 229, pages 411-413 (1991)). Though  $\text{PGF}_{2\alpha}$ -type molecules lower IOP, these types of molecules have also been associated with undesirable side effects resulting from topical ophthalmic dosing. Such effects include an initial increase in IOP, breakdown of the blood aqueous barrier and conjunctival hyperemia (Alm, *The Potential of Prostaglandin Derivatives in Glaucoma Therapy*, Current Opinion in  
10 Ophthalmology, volume 4, No. 11, pages 44-50 (1993)). Based on the foregoing, a need exists for the development of compounds that may activate the  $\text{PGF}_{2\alpha}$  receptors, yielding a more efficacious lowering of IOP, while exhibiting fewer or reduced side effects.

An agent which exhibits comparable efficacy, but with reduced side effects when  
15 compared to other agents, is said to have an improved therapeutic profile. It is an object of this invention to provide a class of IOP lowering agents with an improved therapeutic profile over  $\text{PGF}_{2\alpha}$ , and methods of their use. It has unexpectedly been found that the presently claimed 15-ketal analogs of  $\text{PGF}_{2\alpha}$  meet this objective. Although etiproston, a  
20 15-ketal prostaglandin and certain analogs thereof are known in the art (U.S. Patent No. 4,088,775 and Skuballa, et al., "15-,15-ketals of Natural Prostaglandins and Prostaglandin Analogues Synthesis and Biological Activities," J. Med. Chem., 21(5):443 (1978)), they are known primarily for their luteolytic properties. See, e.g. The Merck Index (Eleventh Ed.) p. 608, monograph no. 3827 (1989). Etiproston was also disclosed in U.S. Patent No. 5,480,900 as one of many prostaglandin analogs which in combination with a clonidine  
25 derivative would be useful for treating glaucoma. In addition, U.S. Patent No. 4,870,104 discloses 11-halo prostaglandins which may have an ethylenedioxyethylene group at the 15 position. The novel compositions and the methods of use claimed in this application, however, are neither disclosed nor suggested in the foregoing art.


### Summary of the Invention

The present invention is directed to novel compounds, ophthalmic compositions and methods of their use in treating glaucoma and ocular hypertension. In particular, the present invention provides certain classes of 15-ketal prostaglandins believed to have functional  $\text{PGF}_{2\alpha}$  receptor agonist activity, and methods of their use in treating glaucoma and ocular hypertension.

### Detailed Description of the Invention

10

It has unexpectedly been found that the 15-ketal substituted  $\text{PGF}_{2\alpha}$  analogs of the present invention exhibit an improved therapeutic profile in the treatment of glaucoma and ocular hypertension when compared to natural prostaglandins and some of their known analogs. The substituted  $\text{PGF}_{2\alpha}$  analogs useful in the methods and compositions of the present invention have the following formula I:



wherein:

20

$R^1 = \text{CO}_2R$ ,  $\text{CONR}^4R^5$ ,  $\text{CH}_2\text{OR}^6$ , or  $\text{CH}_2\text{NR}^7R^8$ , where:

$R = \text{H}$  or cationic salt moiety, or  $\text{CO}_2R =$  pharmaceutically acceptable ester moiety;  $R^4, R^5 =$  same or different  $= \text{H}$  or alkyl;  $R^6 = \text{H}$ , acyl, or alkyl;  $R^7, R^8 =$  same or different  $= \text{H}$ , acyl, or alkyl; with the proviso that if one of  $R^7, R^8 =$  acyl, then the other  $= \text{H}$  or alkyl;

25

$n = 0$  or  $2$ ;

$R^2 = \text{H, alkyl, or acyl;}$

$R^3 = \text{H, halo, or OR}^9$ ; where  $R^9 = \text{H, alkyl, or acyl;}$

5 ----- = single or non-cumulated double bond, with the provisos that if a double bond is present between carbons 4 and 5, it is of the *cis* configuration; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;


$X = (\text{CH}_2)_m \text{ or } (\text{CH}_2)_m\text{O, where } m = 1-6; \text{ and}$

10

$Y = \text{phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy; or}$

$X-Y = (\text{CH}_2)_p Y^1$ ; where  $p = 0-6$ ; and

15



wherein:

20

$W = \text{CH}_2, \text{O, S(O)}_q, \text{NR}^{10}, \text{CH}_2\text{CH}_2, \text{CH=CH, CH}_2\text{O, CH}_2\text{S(O)}_q, \text{CH=N, or CH}_2\text{NR}^9$ ,  
 where  $q = 0-2$ , and  $R^{10} = \text{H, alkyl, or acyl;}$

$Z = \text{H, alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or}$   
 25 hydroxy; and

----- = single or double bond.

For purposes of the foregoing and following definitions, the term  
“pharmaceutically acceptable ester” means any ester that would, in appropriate doses, be  
suitable for therapeutic administration to a patient by conventional means without  
significant deleterious health consequences; and “ophthalmically acceptable ester” means  
5 any pharmaceutically acceptable ester that would be suitable for ophthalmic application,  
i.e. non-toxic and non-irritating. Preferred are alkyl esters. Most preferred are C<sub>2</sub>-C<sub>4</sub> alkyl  
esters, and especially isopropyl esters. In addition, references to “carbons 4 and 5”,  
“carbons 5 and 6” and “carbons 13 and 14” shall mean the carbons so designated in the  
structural formulas even when n = 2.

10

Preferred for use in the methods and compositions of the present invention are  
those compounds of formula I above, wherein:

$R^1 = CO_2R$ , where R = H; or  $CO_2R$  = ophthalmically acceptable ester moiety;

15

n = 0;

$R^2 = H$ ;

20

$R^3 = OH$  in the alpha ( $\alpha$ ) configuration, or Cl or F in the beta ( $\beta$ ) configuration;

---- = single or non-cumulated double bond, with the provisos that if double bond is  
present between carbons 4 and 5 or carbons 5 and 6, it is of the *cis* configuration; and that  
if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;







25

X = CH<sub>2</sub>O; and

Y = phenyl, optionally substituted with halo or trihalomethyl.



Especially preferred for use in the present invention are the following compounds:

Compound Number	Compound Name	Compound Structure
<b>II</b>	(5 <i>Z</i> ,13 <i>E</i> )-(9 <i>S</i> ,11 <i>R</i> )-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester	
<b>III</b>	(5 <i>Z</i> )-(9 <i>S</i> ,11 <i>R</i> )-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5-prostenoic acid isopropyl ester	
<b>IV</b>	(4 <i>Z</i> ,13 <i>E</i> )-(9 <i>S</i> ,11 <i>R</i> )-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-4,13-prostadienoic acid isopropyl ester	
<b>V</b>	(5 <i>Z</i> ,13 <i>E</i> )-(9 <i>S</i> ,11 <i>S</i> )-16-(3-Chlorophenoxy)-11-fluoro-9-hydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester	
<b>VI</b>	(5 <i>Z</i> ,13 <i>E</i> )-(9 <i>S</i> ,11 <i>R</i> )-9,11-Dihydroxy-15,15-(ethylenedioxy)-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester	
<b>VII</b>	(5 <i>Z</i> ,13 <i>E</i> )-(9 <i>S</i> ,11 <i>S</i> )-11-Chloro-16-(3-chlorophenoxy)-15,15-(ethylenedioxy)-9-hydroxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester	

Included within the scope of the present invention are the individual enantiomers  
 5 of the title compounds, as well as their racemic and non-racemic mixtures. The individual enantiomers can be enantioselectively synthesized from the appropriate enantiomerically pure or enriched starting material by means such as those described below. Alternatively, they may be enantioselectively synthesized from racemic/non-racemic or achiral starting materials. (*Asymmetric Synthesis* by J. D. Morrison and J. W. Scott, Eds., Academic Press  
 10 Publishers: New York, 1983-1985 (five volumes) and *Principles of Asymmetric Synthesis*

by R.E. Gawley and J. Aube, Eds., Elsevier Publishers: Amsterdam, 1996). They may also be isolated from racemic and non-racemic mixtures by a number of known methods, e.g. by purification of a sample by chiral HPLC (*A Practical Guide to Chiral Separations by HPLC*, G. Subramanian, Ed., VCH Publishers: New York, 1994; *Chiral Separations by HPLC*, A.M. Krstulovic, Ed., Ellis Horwood Ltd. Publishers, 1989), or by enantioselective hydrolysis of a carboxylic acid ester sample by an enzyme (Ohno, M.; Otsuka, M. Organic Reactions, volume 37, page 1 (1989)). Those skilled in the art will appreciate that racemic and non-racemic mixtures may be obtained by several means, including without limitation, nonenantioselective synthesis, partial resolution or even mixing samples having different enantiomeric ratios.

The compounds of the present invention believed to be novel are the *cis*  $\Delta^4$  compounds, i.e. those compounds of formula I, wherein:

$R^1 = CO_2R$ ,  $CONR^4R^5$ ,  $CH_2OR^6$ , or  $CH_2NR^7R^8$ ; where:

$R = H$  or cationic salt moiety, or  $CO_2R =$  pharmaceutically acceptable ester moiety;  $R^4, R^5 =$  same or different  $= H$  or alkyl;  $R^6 = H$ , acyl, or alkyl;  $R^7, R^8 =$  same or different  $= H$ , acyl, or alkyl; with the proviso that if one of  $R^7, R^8 =$  acyl, then the other  $= H$  or alkyl;

$n = 0$  or  $2$ ;

$R^2 = H$ , alkyl, or acyl;

$R^3 = H$ , halo, or  $OR^9$ ; where  $R^9 = H$ , alkyl, or acyl;


---- = single or non-cumulated double bond, with the provisos that a *cis* double bond is present between carbons 4 and 5; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

$X = (CH_2)_m$  or  $(CH_2)_mO$ , where  $m = 1-6$ ; and

$Y =$  phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy; or

5

$X-Y = (CH_2)_p Y^1$ ; where  $p = 0-6$ ; and



10

wherein:

$W = CH_2, O, S(O)_q, NR^{10}, CH_2CH_2, CH=CH, CH_2O, CH_2S(O)_q, CH=N$ , or  $CH_2NR^9$ ,

where  $q = 0-2$ , and  $R^{10} = H$ , alkyl, or acyl;

15

$Z = H$ , alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or hydroxy; and

---- = single or double bond.

20

Preferred novel compounds are those of formula I, wherein:

$R^1 = CO_2R$ ; where  $R = H$ ; or  $CO_2R =$  pharmaceutically acceptable ester moiety;

25

$n = 0$ ;

$R^2 = H$ ;

$R^3$  = OH in the alpha ( $\alpha$ ) configuration, or Cl or F in the beta ( $\beta$ ) configuration;

---- = single or non-cumulated double bond, with the provisos that a *cis* double bond is present between carbons 4 and 5 and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

X = CH<sub>2</sub>O; and

Y = phenyl, optionally substituted with halo, or trihalomethyl.

10

Other related PGFs within the scope of the present invention are known and their syntheses are either described in the literature or can be achieved by methods similar to those described in the literature or otherwise known to those of skill in the art (*e.g.* Skuballa *et. al.* U.S. Patent No. 4,088,775; Vorbruggen *et. al.* U.S. Patent No. 4,870,104).

15 The foregoing references are by this reference incorporated herein.

In the foregoing illustrations, as well as those provided hereinafter, wavy line attachments indicate either the alpha ( $\alpha$ ) or beta ( $\beta$ ) configuration. The carbon numbering is as indicated in structural formula I, even when  $n = 2$ . A hatched line, as used *e.g.* at carbon 9, indicates the  $\alpha$  configuration. A solid triangular line indicates the  $\beta$  configuration. Dashed lines on bonds, *e.g.* between carbons 5 and 6, indicate a single or double bond. Two solid lines between carbons indicate a double bond of the specified configuration.


20

25 In the following Examples 1-6, the following standard abbreviations are used:  
g = grams (mg = milligrams); mol = moles (mmol = millimoles); mL = milliliters;  
mm Hg = millimeters of mercury; mp = melting point; bp = boiling point; h = hours; and  
min = minutes. In addition, "NMR" refers to nuclear magnetic resonance spectroscopy  
and "MS" refers to mass spectrometry.

30

## EXAMPLE 1:

## Preparation of II



A. [3aR,4R(1E),5R,6aS]-5-(Benzoyloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (2)

To a solution of [3aR,4R(1E),5R,6aS]-5-(benzoyloxy)-4-[4-(3-chlorophenoxy)-3-oxobutenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (1; for preparation see published European Patent Application No. EP 639563 A2, which is incorporated by this reference) (1.32 g, 3.0 mmol), 4A molecular sieves (1.27 g), and 1,2-bis(trimethylsiloxy)ethane (1.27 g, 6.18 mmol) in methylene chloride (23 mL) at -78°C (bath temperature) was added trimethylsilyl trifluoromethanesulfonate (172 mg, 0.77 mmol). The reaction was then warmed to -20 °C and maintained at that temperature overnight. Triethylamine (0.8 mL) was added, the solution was warmed to room temperature, saturated sodium bicarbonate (15 mL) was added, the layers were separated, the aqueous phase was extracted with methylene chloride (2 x 20 mL), the combined organic layers were dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 19 cm tall x 26 mm diameter silica gel column eluting with 1:1 ethyl acetate:hexane to afford **2** (1.41 g, 97%). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 176.17 (C), 165.92 (C), 159.23 (C), 134.71 (C), 133.32 (CH), 131.06 (CH), 130.06 (CH), 129.56 (CH), 129.40 (CH), 128.48 (CH), 121.37 (CH), 115.14 (CH), 113.21 (CH), 106.27 (C), 83.10 (CH), 78.76 (CH), 71.36 (CH<sub>2</sub>), 65.41 (CH<sub>2</sub>), 65.23 (CH<sub>2</sub>), 53.74 (CH), 42.47 (CH), 37.35 (CH<sub>2</sub>), 34.79 (CH<sub>2</sub>).

20

B. [3aR,4R(1E),5R,6aS]-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-5-hydroxy-hexahydro-2H-cyclopenta[b]furan-2-one (3)

To a solution of **2** (1.64 g, 3.38 mmol) in methanol (25 mL) was added potassium carbonate (480 mg, 3.47 mmol). After 18 h, saturated ammonium chloride (45 mL) was added, the mixture was extracted with ethyl acetate (3 x 30 mL), dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 20 cm tall x 26 mm diameter silica gel column eluting with 1:1 ethyl acetate:hexane to afford **3** (201 mg, 16%).

25

C. [3a*R*,4*R*(1*E*),5*R*,6a*S*]-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2*H*-cyclopenta[*b*]furan-2-one (4)

To a solution of 3 (200 mg, 0.52 mmol), imidazole (125 mg, 1.84 mmol) and 4-  
5 (dimethylamino)pyridine (DMAP) (28 mg, 0.23 mmol) in methylene chloride (4 mL) was  
added *t*-butyldiphenylsilyl chloride (200 mg, 0.73 mmol). After 40, min saturated  
ammonium chloride (15 mL) was added, the solution was extracted with methylene  
chloride (3 x 15 mL), dried (magnesium sulfate), filtered, concentrated, and  
chromatographed on a 14 cm tall x 26 mm diameter silica gel column eluting with 40%  
10 ethyl acetate in hexane to afford 4 (316 mg, 98%).

D. [3a*R*,4*R*(1*E*),5*R*,6a*S*]-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2*H*-cyclopenta[*b*]furan-2-ol (5)

15 To a solution of 4 (310 mg, 0.50 mmol) in toluene (7 mL) at -78°C (bath  
temperature) was added a 1.5 *M* solution of diisobutylaluminum hydride (DIBAL-H) in  
toluene (0.46 mL, 0.69 mmol). After 1 h, a 1:1 v:v solution of ethyl acetate:methanol (4  
mL) was added, the solution was warmed to room temperature, saturated ammonium  
chloride (30 mL) and ethyl acetate (30 mL) were added, the thick mixture was filtered  
20 through Celite, the phases were separated, the aqueous layer was extracted with ethyl  
acetate (2 x 30 mL), the combined organic layers were dried (magnesium sulfate), filtered,  
and concentrated to afford crude 5 (320 mg, 100%), which was used directly in the next  
step without further purification.

25 E. (5*Z*,13*E*)-(9*S*,11*R*)-11-(*t*-Butyldiphenylsiloxy)-16-(3-chlorophenoxy)-15,15-(ethylenedioxy)-9-hydroxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester  
(6)

To a suspension of (4-carboxybutyl)triphenylphosphonium bromide (685 mg, 1.55  
30 mmol) in THF (7 mL) at 0°C (bath temperature) was added a 1 *M* solution of potassium *t*-

butoxide in THF (3.1 mL, 3.1 mmol). After 12 min, **5** (320 mg, 0.5 mmol) was added as a solution in THF (7 mL); and after 40 min, additional portions of (4-carboxybutyl)triphenylphosphonium bromide (700 mg, 1.58 mmol) and potassium *t*-butoxide (6 mL, 6 mmol) were added. After an additional 45 min, saturated ammonium chloride (20 mL) was added, the solution extracted with ethyl acetate (3 x 25 mL), dried (magnesium sulfate), filtered, and concentrated to afford an oil. To a solution of this oil, DMAP (45 mg, 0.37 mmol), isopropanol (1.0 g, 16.7 mmol), and 4A molecular sieves (300 mg) in methylene chloride (6.5 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (320 mg, 1.67 mmol). After 18 h, saturated ammonium chloride (25 mL) was added, the layers were separated, the aqueous phase was extracted with methylene chloride (2 x 20 mL), the combined organic layers were dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 17 cm tall x 26 mm diameter silica gel column eluting with 30% ethyl acetate in hexane to afford **6** and the chromatographically separable siloxy transposition isomer **6\*** (121 mg combined, 32%).


**F. (5Z,13E)-(9S,11R)-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester (II)**

To a solution of a mixture of **6** and **6\*** (34 mg, 0.045 mmol) in THF (3 mL) was added a 1 M solution of tetrabutylammonium fluoride (TBAF) in THF (0.2 mL, 0.2 mmol). After 1 h, saturated ammonium chloride (3 mL) was added, the solution was extracted with ethyl acetate (4 x 3 mL), concentrated, and chromatographed on a 19 cm tall x 10 mm diameter silica gel column eluting with 9:1 ethyl acetate:hexane to afford **II** (18.2 mg, 79%). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.39 (C), 159.45 (C), 134.76 (C), 134.68 (CH), 130.14 (CH), 129.88 (CH), 128.89 (CH), 128.11 (CH), 121.28 (CH), 115.29 (CH), 113.30 (CH), 106.62 (C), 78.31 (CH), 73.36 (CH), 71.47 (CH<sub>2</sub>), 67.63 (CH), 65.34 (CH<sub>2</sub>), 65.32 (CH<sub>2</sub>), 55.76 (CH), 50.74 (CH), 42.89 (CH<sub>2</sub>), 33.99 (CH<sub>2</sub>), 26.61 (CH<sub>2</sub>), 25.82 (CH<sub>2</sub>), 24.84 (CH<sub>2</sub>), 21.83 (CH<sub>3</sub>). MS, m/z calcd. for C<sub>27</sub>H<sub>37</sub>O<sub>7</sub>ClNa [(M + Na)<sup>+</sup>], 531; found, 531.



## EXAMPLE 2:

## Preparation of III



A. (3aR,4R,5R,6aS)-5-(Benzoyloxy)-4-[4-(3-chlorophenoxy)-3-oxobutyl]-hexahydro-2H-cyclopenta[b]furan-2-one (8)

To a 2 M solution of oxalyl chloride in methylene chloride (3.7 mL, 7.4 mmol) at  
5 -78°C (bath temperature) was added a solution of dimethylsulfoxide (660 mg, 8.46 mmol)  
in methylene chloride (0.5 mL). After 10 min, a solution of [(3aR,4R(3R),5R,6aS)-5-  
(benzoyloxy)-4-[4-(3-chlorophenoxy)-3-hydroxybutyl]-hexahydro-2H-cyclopenta[b]furan-  
2-one (7; for preparation see published European Patent Application No. EP 639563 A2)  
(1.60 g, 3.6 mmol) in methylene chloride (25 mL) was added dropwise. After an  
10 additional 2 h, triethylamine (1.31 g, 12.9 mmol) was added, the reaction was warmed to  
room temperature, saturated ammonium chloride (50 mL) was added, the solution was  
extracted with methylene chloride (3 x 40 mL), dried (magnesium sulfate), filtered,  
concentrated, and chromatographed on a 16 cm tall x 41 mm diameter silica gel column  
eluting with 1:1 ethyl acetate:hexane to afford 8 (1.17 g, 73%).

15

B. (3aR,4R,5R,6aS)-5-(Benzoyloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butyl]-hexahydro-2H-cyclopenta[b]furan-2-one (9)

To a solution of 8 (1.29 g, 2.91 mmol), 4A molecular sieves (1.7 g) and 1,2-  
20 bis(trimethylsiloxy)ethane (1.2 g, 5.8 mmol) in methylene chloride (20 mL) at 0°C (bath  
temperature) was added trimethylsilyl trifluoromethanesulfonate (170 mg, 0.76 mmol).  
After 2 h, the reaction was warmed to room temperature, cooled to 4°C (bath temperature)  
and maintained at that temperature over 72 h. Triethylamine (1 mL) and saturated sodium  
bicarbonate (20 mL) were added sequentially, the solution was extracted with ethyl acetate  
25 (3 x 35 mL), dried (magnesium sulfate), filtered, concentrated, and chromatographed on a  
17 cm tall x 26 mm diameter silica gel column eluting with 1:1 ethyl acetate:hexane to  
afford 9 (1.20 g, 84%). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 176.75 (C), 166.00 (C), 159.22 (C), 134.87  
(C), 133.22 (CH), 130.23 (CH), 129.65 (CH), 129.61 (CH), 128.48 (CH), 121.42 (CH),  
115.04 (CH), 113.12 (CH), 108.78 (C), 84.41 (CH), 80.26 (CH), 70.15 (CH<sub>2</sub>), 65.67

(CH<sub>2</sub>), 65.62 (CH<sub>2</sub>), 52.70 (CH), 43.40 (CH), 37.61 (CH<sub>2</sub>), 36.27 (CH<sub>2</sub>), 33.00 (CH<sub>2</sub>), 26.60 (CH<sub>2</sub>).

5 C. (3aR,4R,5R,6aS)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butyl]-5-hydroxy-hexahydro-2H-cyclopenta[b]furan-2-one (10)

To a solution of 9 (1.15 g, 2.36 mmol) in methanol (40 mL) was added potassium carbonate (389 mg, 2.81 mmol). After 3.5 h, saturated ammonium chloride (45 mL) and saturated brine (25 mL) were added, the mixture was extracted with ethyl acetate (3 x 60  
10 mL), dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 14 cm tall x 41 mm diameter silica gel column eluting with 4:1 ethyl acetate:hexane to afford 10 (708 mg, 81%).

15 D. (3aR,4R,5R,6aS)-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butyl]-hexahydro-2H-cyclopenta[b]furan-2-one (11)

To a solution of 10 (700 mg, 1.89 mmol), DMAP (58 mg, 0.48 mmol), and imidazole (192 mg, 2.82 mmol) in methylene chloride (11 mL) was added *t*-butyldiphenylsilyl chloride (670 mg, 2.45 mmol). After 4.5 h, saturated ammonium  
20 chloride (15 mL) was added, the phases were separated, the aqueous layer was extracted with methylene chloride (2 x 15 mL), the combined organic layers were dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 22 cm tall x 26 mm diameter silica gel column eluting with 40% ethyl acetate in hexane to afford 11 (951 mg, 83%).

25 E. (3aR,4R,5R,6aS)-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butyl]-hexahydro-2H-cyclopenta[b]furan-2-ol (12)

To a solution of 11 (945 mg, 1.55 mmol) in toluene (11 mL) at -78°C (bath temperature) was added a 1.5 M solution of DIBAL-H in toluene (3.0 mL, 4.5 mmol).  
30 After 3.5 h, ethyl acetate (10 mL) was added, the mixture was warmed to room

temperature, saturated sodium potassium tartarate (20 mL) was added, and the thick solution was stirred for 30 min to break the emulsion. The layers were separated, the aqueous phase was extracted with ethyl acetate (2 x 30 mL), the combined organic layers were dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 13 cm  
5 tall x 26 mm diameter silica gel column eluting with 40% ethyl acetate in hexane to afford 12 (968 mg, 100%).

F. (5Z)-(9S,11R)-11-(*t*-Butyldiphenylsiloxy)-16-(3-chlorophenoxy)-15,15-(ethylenedioxy)-9-hydroxy-17,18,19,20-tetranor-5-prostenoic acid isopropyl ester (13)

10


To a suspension of (4-carboxybutyl)triphenylphosphonium bromide (2.1 g, 4.7 mmol) in THF (22 mL) at 0°C (bath temperature) was added a 1 M solution of potassium *t*-butoxide in THF (9.4 mL, 9.4 mmol). After 15 min, a solution of 12 (960 mg, 1.57 mmol) in THF (13 mL) was added dropwise. After an additional 4 h, saturated  
15 ammonium chloride (30 mL) was added, the mixture was extracted with ethyl acetate (3 x 30 mL), dried (magnesium sulfate), filtered, and concentrated to afford a crude oil. This oil was dissolved in acetone (15 mL), the bath temperature was lowered to 0°C, and DBU (1.4 g, 9.2 mmol) was added. After 20 min, isopropyl iodide (1.6 g, 9.4 mmol) was added, and the mixture was warmed to room temperature and stirred over 3 d. Saturated  
20 ammonium chloride (25 mL) was added, the mixture was extracted with ethyl acetate (3 x 25 mL), dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 17 cm tall x 26 mm diameter silica gel column eluting with 30% ethyl acetate in hexane to afford 13 and the siloxy transposition isomer 13\* (791 mg combined, 67%).

25 G. (5Z)-(9S,11R)-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5-prostenoic acid isopropyl ester (III)

To a solution of the above mixture of 13 and 13\* (785 mg, 1.05 mmol) in THF (10 mL) was added a 1 M solution of TBAF in THF (3 mL, 3 mmol). After 1 h, saturated  
30 ammonium chloride (40 mL) was added, the mixture was extracted with ethyl acetate (3 x

30 mL), dried (magnesium sulfate), filtered, concentrated, and chromatographed on a 22 cm tall x 26 mm diameter silica gel column eluting with 1:1 ethyl acetate:hexane to afford **III** (392 mg, 73%).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  173.36 (C), 159.37 (C), 134.81 (C), 130.18 (CH), 129.66 (CH), 129.22 (CH), 121.28 (CH), 115.07 (CH), 113.63 (CH), 109.17 (C), 78.65 (CH), 74.72 (CH), 70.29 ( $\text{CH}_2$ ), 67.57 (CH), 65.67 ( $\text{CH}_2$ ), 65.56 ( $\text{CH}_2$ ), 52.93 (CH), 51.79 (CH), 42.43 ( $\text{CH}_2$ ), 34.04 ( $\text{CH}_2$ ), 33.58 ( $\text{CH}_2$ ), 26.93 ( $\text{CH}_2$ ), 26.88 ( $\text{CH}_2$ ), 26.64 ( $\text{CH}_2$ ), 24.90 ( $\text{CH}_2$ ), 21.82 ( $\text{CH}_3$ ). MS,  $m/z$  calcd. for  $\text{C}_{27}\text{H}_{39}\text{O}_7\text{ClNa}$   $[(\text{M} + \text{Na})^+]$ , 533; found, 533.

10


**EXAMPLE 3:****Synthesis of IV**

(4Z,13E)-(9S,11R)-16-(3-Chlorophenoxy)-9,11-dihydroxy-15,15-(ethylenedioxy)-  
17,18,19,20-tetranor-4,13-prostadienoic acid isopropyl ester (IV)

Reaction of alcohol **3** with 3,4-dihydro-2*H*-pyran in CH<sub>2</sub>Cl<sub>2</sub> at 0°C in the presence  
5 of *p*-toluenesulfonic acid affords **14**, reduction of which with DIBAL-H in toluene at -78  
°C provides lactol **15**. Wittig reaction of lactol **15** with Ph<sub>3</sub>P<sup>+</sup>CH<sub>2</sub>OMe Cl<sup>-</sup> in the the  
presence of potassium *t*-butoxide in THF affords enol ether **16** as a mixture of enol ether  
olefin geometrical isomers. Treatment of this mixture with *p*-toluenesulfonic acid in  
THF/water affords lactol **17**. Wittig reaction of **17** with Ph<sub>3</sub>P<sup>+</sup>(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>H Br<sup>-</sup> in the  
10 presence of potassium *t*-butoxide in THF, followed by treatment of an acetone solution of  
the resulting carboxylic acid with DBU and isopropyl iodide, yields **IV** after purification  
via silica gel chromatography.

## EXAMPLE 4:

## Synthesis of V




(5Z,13E)-(9S,11S)-16-(3-Chlorophenoxy)-11-fluoro-9-hydroxy-15,15-(ethylenedioxy)-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester (V)

Reduction of aldehyde **18** to alcohol **19** is accomplished using NaBH<sub>4</sub> in a 1:1  
5 mixture of CH<sub>2</sub>Cl<sub>2</sub>:MeOH. Silylation to **20** is accomplished *via* treatment with  
Ph<sub>2</sub>Bu'SiCl, imidazole, 4-(dimethylamino)pyridine in CH<sub>2</sub>Cl<sub>2</sub>. Debenzoylation is effected  
with K<sub>2</sub>CO<sub>3</sub> in MeOH to provide **21**. Fluorination with (diethylamino)sulfur trifluoride in  
CH<sub>2</sub>Cl<sub>2</sub> at 0 °C affords a mixture of **22** and an elimination by-product **23**. This mixture is  
treated with OsO<sub>4</sub> and 4-methylmorpholine *N*-oxide in acetone/water to afford a now  
10 easily chromatographically separable mixture of **22** and a dihydroxylation product of **23**.  
Desilylation of **22** with TBAF in THF yields alcohol **24**, which is oxidized to aldehyde **25**  
using Swern conditions (oxalyl chloride/DMSO). Horner-Emmons reaction of **25** with  
dimethyl [3-(3-chlorophenoxy)-2-oxopropyl]phosphonate in THF in the presence of  
NEt<sub>3</sub>/LiCl affords enone **26**. Ketalization is achieved by treatment with 1,2-  
15 bis(trimethylsiloxy)ethane and trimethylsilyl trifluoromethanesulfonate in CH<sub>2</sub>Cl<sub>2</sub> from  
-78°C to -20°C overnight to give **27**. Reduction of **27** with 1 equivalent of DIBAL-H in  
toluene at -78°C provides lactol **28**. Wittig reaction with Ph<sub>3</sub>P<sup>+</sup>(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>H Br<sup>-</sup> in THF in  
the presence of potassium *t*-butoxide, followed by esterification of an acetone solution of  
the resulting acid with isopropyl iodide/DBU, affords **V** after purification *via* silica gel  
20 chromatography.



## EXAMPLE 5:

## Synthesis of VI



A. [3aR,4R(1E),5R,6aS]-5-(Benzoyloxy)-4-(4-phenoxy-3-oxobutyl)-hexahydro-2H-cyclopenta[b]furan-2-one (29)

To a solution of lithium chloride (920 mg, 22 mmol) and dimethyl (2-oxo-3-  
5 phenoxypropyl)phosphonate (prepared in a manner analogous to that described in U.S.  
Patent No. 5,665,773 for dimethyl (2-oxo-3-(3-chlorophenoxy)propyl)phosphonate, which  
patent is incorporated herein by this reference) (3.50 g, 13.6 mmol) in THF (30 mL) at 0°C  
(bath temperature) was added NEt<sub>3</sub> (1.20 g, 11.9 mmol). After 10 min, aldehyde 18 was  
added in one portion to the suspension. After 2 h, the suspension was added to saturated  
10 NH<sub>4</sub>Cl (30 mL), the mixture was extracted with ethyl acetate (3 x 30 mL), dried (MgSO<sub>4</sub>),  
filtered, concentrated, and chromatographed on a 15 cm tall x 41 mm diameter silica gel  
column eluting with 1:1 ethyl acetate:hexane to afford 29 (1.30 g, 40 %).

B. [3aR,4R(1E),5R,6aS]-5-(Benzoyloxy)-4-[4-(3-chlorophenoxy)-3,3-  
15 (ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (30)

To a solution of enone 29 (1.30 g, 3.2 mmol) and 1,2-bis(trimethylsiloxy)ethane  
(1.34 g, 6.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at -78°C (bath temperature) was added  
trimethylsilyl trifluoromethanesulfonate (240 mg, 1.1 mmol). After 1 h, the reaction was  
20 warmed to -20°C and kept at that temperature overnight. The reaction was quenched by  
the addition of NEt<sub>3</sub> (360 mg, 3.56 mmol), warmed to room temperature, added to  
saturated sodium bicarbonate (25 mL), the layers were separated, the aqueous layer was  
extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 25 mL), ), dried (MgSO<sub>4</sub>), filtered, concentrated, and  
chromatographed on a 12 cm tall x 41 mm diameter silica gel column to afford 30 (1.19 g,  
25 82%).

C. [3aR,4R(E),5R,6aS]-5-Hydroxy-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (31)

To a solution of 30 (1.18 g, 2.62 mmol) in methanol (15 mL) was added K<sub>2</sub>CO<sub>3</sub> (400 mg, 2.89 mmol). After 2.5 h, saturated NH<sub>4</sub>Cl was added (35 mL), the mixture was extracted with ethyl acetate (3 x 40 mL), dried (MgSO<sub>4</sub>), filtered, concentrated, and chromatographed on a 16 cm tall x 41 mm diameter silica gel column eluting first with 3:2 ethyl acetate:hexane and then with ethyl acetate to afford 31 (600 mg, 66%).

D. [3aR,4R(E),5R,6aS]-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (32)

To a solution of 31 (590 mg, 1.7 mmol), imidazole (168 mg, 2.47 mmol), and DMAP (50 mg, 0.41 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added *t*-butyldiphenylsilyl chloride (590 mg, 2.15 mmol). After 1 h, saturated NH<sub>4</sub>Cl was added (25 mL), the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 25 mL), dried (MgSO<sub>4</sub>), filtered, concentrated, and chromatographed on a 16 cm tall x 26 mm diameter silica gel column eluting with 1:1 ethyl acetate:hexane to afford 32 contaminated with some Bu<sup>t</sup>Ph<sub>2</sub>SiOH (1.09 g); the mixture was used in the next step without any further purification.

E. [3aR,4R(E),5R,6aS]-5-(*t*-Butyldiphenylsiloxy)-4-[4-(3-chlorophenoxy)-3,3-(ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-ol (33)

To the above 32: Bu<sup>t</sup>Ph<sub>2</sub>SiOH mixture (1.09 g) in toluene (5.5 mL) at -78°C (bath temperature) was added DIBAL-H (1.6 mL of a 1.5 M solution in toluene, 2.4 mmol). After 2 h, methanol (3 mL) and ethyl acetate (3 mL) were added, the solution was warmed to room temperature, saturated sodium potassium tartrate (20 mL) was added, and the mixture was stirred for 40 min. The solution was extracted with ethyl acetate (2 x 40 mL), dried (MgSO<sub>4</sub>), filtered, concentrated, and chromatographed on a 15 cm tall x 26 mm

diameter silica gel column eluting with 1:1 ethyl acetate:hexane to afford **33** (915 mg, 92% from **31**).

5 F. (5Z,13E)-(9S,11R)-11-(*t*-Butyldiphenylsiloxy)-15,15-(ethylenedioxy)-9-hydroxy-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester (**34**)

To a suspension of (4-carboxybutyl)triphenylphosphonium bromide (2.26 g, 5.1 mmol) in THF (10 mL) at 0°C (bath temperature) was added a 1 M solution of potassium *t*-butoxide in THF (12 mL, 12 mmol). After 30 min, lactol **33** was added (910 mg, 1.5 mmol) as a solution in THF (10 mL). After an additional 35, min saturated NH<sub>4</sub>Cl was added (35 mL), the solution was extracted with ethyl acetate (3 x 35 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated to afford an oil. The oil was dissolved in acetone (15 mL), cooled to 0°C (bath temperature), and DBU was added (1.2 g, 7.9 mmol). After 25 min, isopropyl iodide was added (1.3 g, 7.8 mmol) and the reaction was warmed to room temperature. After stirring overnight, the solution was added to saturated NH<sub>4</sub>Cl (25 mL), extracted with ethyl acetate (3 x 30 mL), dried (MgSO<sub>4</sub>), filtered, concentrated, and chromatographed on a 17 cm tall x 26 mm diameter silica gel column eluting with 40% ethyl acetate in hexane to afford **34** as a chromatographically separable mixture with the siloxy transpositional isomer **34\*** (913 mg total, 83%).

20


G. (5Z,13E)-(9S,11R)-9,11-Dihydroxy-15,15-(ethylenedioxy)-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester (**VI**)

To a solution of a mixture of **34** and **34\*** (510 mg, 0.72 mmol) in THF (6 mL) was added a 1 M solution of TBAF in THF (1.7 mL, 1.7 mmol). After 2 h, saturated NH<sub>4</sub>Cl was added (20 mL), the solution was extracted with ethyl acetate (3 x 30 mL), dried (MgSO<sub>4</sub>), filtered, concentrated, and chromatographed on a 15 cm tall x 41 mm diameter silica gel column eluting with ethyl acetate to afford **VI** (194 mg, 57%). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.67 (C), 158.75 (C), 134.45 (CH), 129.77 (CH), 129.36 (CH), 128.96 (CH), 128.35 (CH), 121.06 (CH), 114.80 (CH), 106.79 (C), 78.22 (CH), 73.28 (CH), 71.26

30

(CH<sub>2</sub>), 67.60 (CH), 65.30 (CH<sub>2</sub>), 65.26 (CH<sub>2</sub>), 55.70 (CH), 50.69 (CH), 42.86 (CH<sub>2</sub>), 34.02 (CH<sub>2</sub>), 26.60 (CH<sub>2</sub>), 25.81 (CH<sub>2</sub>), 24.85 (CH<sub>2</sub>), 21.83 (CH<sub>3</sub>). MS, m/z calcd. for C<sub>27</sub>H<sub>38</sub>O<sub>7</sub>Na [(M + Na)<sup>+</sup>], 497; found, 497.

5

**EXAMPLE 6:****Synthesis of VII**

(5Z,13E)-(9S,11S)-11-Chloro-16-(3-chlorophenoxy)-15,15-(ethylenedioxy)-9-hydroxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester (VII)

Treatment of alcohol 3 (see Example 1) with 4-methoxybenzyl chloride, (*i*-  
5  $\text{C}_3\text{H}_7$ )<sub>2</sub>NCH<sub>2</sub>CH<sub>3</sub>, and Bu<sub>4</sub>N<sup>+</sup>I<sup>-</sup> in CH<sub>2</sub>Cl<sub>2</sub> affords lactone 35, which is reduced to lactol 36  
by DIBAL in toluene at -78 °C. Wittig olefination with Ph<sub>3</sub>P<sup>+</sup>(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>H Br<sup>-</sup> in THF in  
the presence of *t*-BuOK, followed by esterification of the resultant carboxylic acid with  
DBU/isopropyl iodide in acetone gives 37. Silylation of the alcohol is effected using *t*-  
butyldiphenylsilyl chloride/imidazole in DMF to afford the silyl ether, 38, which is  
10 converted to alcohol 39 by DDQ in CH<sub>2</sub>Cl<sub>2</sub>/water. Treatment of 39 with CH<sub>3</sub>SO<sub>2</sub>Cl and  
NEt<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, followed by heating with Bu<sub>4</sub>NCl in toluene, yields chloride 40.  
Deprotection of 40 with TBAF in THF affords VII.

The 15-ketal substituted prostaglandins of the present invention may be formulated  
15 in various pharmaceutical compositions for administering to humans and other mammals  
as a treatment of glaucoma or ocular hypertension. As used herein, the term  
"pharmaceutically effective amount" refers to that amount of a compound of the present  
invention which lowers IOP when administered to a patient, especially a mammal. The  
preferred route of administration is topical. The compounds of the present invention can  
20 be administered as solutions, suspensions, or emulsions (dispersions) in an ophthalmically  
acceptable vehicle. As used herein, the term "ophthalmically acceptable vehicle" refers to  
any substance or combination of substances which are non-reactive with the compounds  
and suitable for administration to a patient. Solubilizers and stabilizers are deemed to be  
non-reactive. Preferred are aqueous vehicles suitable for topical administration to the  
25 patient's eyes.

In forming compositions for topical administration, the compounds of the present invention are generally formulated as between about 0.00003 to about 0.5 percent by weight (wt%) solutions in water at a pH between about 4.5 to about 8.0, preferably between about 7.0 and about 7.5. The compounds are preferably formulated as between  
5 about 0.0005 to about 0.03 wt% and, most preferably, between about 0.001 and about 0.01 wt%. While the precise regimen is left to the discretion of the clinician, it is recommended that the resulting solution be topically applied by placing one drop in each eye one or two times a day.

10 Other ingredients which may be desirable to use in the ophthalmic preparations of the present invention include preservatives, co-solvents and viscosity building agents.

Antimicrobial Preservatives:

Ophthalmic products are typically packaged in multidose form. Preservatives are  
15 thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. Such preservatives are typically employed at a level between about 0.001% and about 1.0% by weight.

20

Co-Solvents:

Prostaglandins, and particularly ester derivatives, typically have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition. Such co-solvents include: Polysorbate 20, 60 and 80; Pluronic F-68, F-84  
25 and P-103; CREMOPHORE<sup>®</sup> EL (polyoxyl 35 castor oil) cyclodextrin; or other agents known to those skilled in the art. Such co-solvents are typically employed at a level between about 0.01% and about 2% by weight.

Viscosity Agents:

Viscosity greater than that of simple aqueous solutions may be desirable to increase ocular absorption of the active compound, to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the ophthalmic formulation. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and other agents known to those skilled in the art. Such agents are typically employed at a level between about 0.01% and about 2% by weight.

Preferred formulations of 15-ketal prostaglandins of the present invention include the following Examples 7-10:

**Example 7**

<b>Ingredient</b>	<b>Amount (wt%)</b>
Compound III	0.001
Phosphate Buffered Saline	1.0
Polysorbate 80	0.5
Purified water	q.s. to 100%



**Example 8**

	<b>Ingredient</b>	<b>Amount (wt%)</b>
5	Compound II	0.001
	Monobasic sodium phosphate	0.05
	Dibasic sodium phosphate (anhydrous)	0.15
10	Sodium chloride	0.75
	Disodium EDTA (Edetate disodium)	0.05
	CREMOPHOR <sup>®</sup> EL	0.1
	Benzalkonium chloride	0.01
	HCl and/or NaOH	pH 7.3 - 7.4
15	Purified water	q.s. to 100%

**Example 9**

	<b>Ingredient</b>	<b>Amount (wt%)</b>
20	Compound IV	0.01
	Phosphate Buffered Saline	1.0
25	Hydroxypropyl- $\beta$ -cyclodextrin	4.0
	Purified water	q.s. to 100%


**Example 10**

<b>Ingredient</b>	<b>Amount (wt%)</b>
Compound VI or VII	0.01
CREMOPHOR <sup>®</sup> EL	0.5
Tromethamine	0.12
Boric Acid	0.3
Mannitol	4.6
Disodium EDTA	0.01
Benzalkonium Chloride	0.01
NaOH and/or HCl	q.s. to pH 7
Purified water	q.s. to 100%

The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

**What is claimed is:**

1. A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:



wherein:

$R^1 = CO_2R$ ,  $CONR^4R^5$ ,  $CH_2OR^6$ , or  $CH_2NR^7R^8$ ; where:

$R = H$  or cationic salt moiety, or  $CO_2R =$  ophthalmically acceptable ester moiety;

$R^4, R^5 =$  same or different  $= H$  or alkyl;  $R^6 = H$ , acyl, or alkyl;  $R^7, R^8 =$  same or different  $= H$ , acyl, or alkyl; with the proviso that if one of  $R^7, R^8 =$  acyl, then the other  $= H$  or alkyl;

$n = 0$  or  $2$

$R^2 = H$ , alkyl, or acyl;


$R^3 = H$ , halo, or  $OR^9$ ; where  $R^9 = H$ , alkyl, or acyl;

---- = single or non-cumulated double bond, with the provisos that if a double bond is present between carbons 4 and 5, it is of the *cis* configuration; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

$X = (CH_2)_m$  or  $(CH_2)_mO$ , where  $m = 1-6$ ; and

Y = phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy; or

X-Y = (CH<sub>2</sub>)<sub>p</sub>Y<sup>1</sup>; where p = 0-6; and



wherein:

W = CH<sub>2</sub>, O, S(O)<sub>q</sub>, NR<sup>10</sup>, CH<sub>2</sub>CH<sub>2</sub>, CH=CH, CH<sub>2</sub>O, CH<sub>2</sub>S(O)<sub>q</sub>, CH=N, or CH<sub>2</sub>NR<sup>9</sup>; where q = 0-2, and R<sup>10</sup> = H, alkyl, or acyl;

Z = H, alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or hydroxy; and

---- = single or double bond.

2. The method of claim 1, wherein the compound is administered topically.
3. The method of claim 2, wherein the compound is administered as a solution, suspension or emulsion.

4. The method of claim 1, wherein:

$R^1 = CO_2R$ , where  $R = H$ ; or  $CO_2R$  = ophthalmically acceptable ester moiety;

$R^2 = H$ ;

$n = 0$ ;

$R^3 = OH$  in the alpha ( $\alpha$ ) configuration, or Cl or F in the beta ( $\beta$ ) configuration;

---- = single or non-cumulated double bond, with the provisos that if double bond is present between carbons 4 and 5 or carbons 5 and 6, it is of the *cis* configuration; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

$X = CH_2O$ ; and


$Y$  = phenyl, optionally substituted with halo or trihalomethyl.

5. The method of claim 2, wherein the concentration of the compound is between about 0.00003 to about 0.5 weight percent.


6. The method of claim 5, wherein the concentration of the compound is between about 0.0005 to about 0.03 weight percent.

7. The method of claim 6, wherein the concentration of the compound is between about 0.001 to about 0.01 weight percent.


8. The method of claim 5, wherein the compound is:




9. The method of claim 5, wherein the compound is:




10. The method of claim 5, wherein the compound is:




11. The method of claim 5, wherein the compound is:




12. The method of claim 5, wherein the compound is:



13. The method of claim 5, wherein the compound is:



14. A compound of formula (I):



wherein:

$R^1 = CO_2R$ ,  $CONR^4R^5$ ,  $CH_2OR^6$ , or  $CH_2NR^7R^8$ ; where:

$R = H$  or cationic salt moiety, or  $CO_2R =$  pharmaceutically acceptable ester moiety;  $R^4, R^5 =$  same or different  $= H$  or alkyl;  $R^6 = H$ , acyl, or alkyl;  $R^7$ ,

$R^8 =$  same or different  $= H$ , acyl, or alkyl; with the proviso that if one of  $R^7$ ,

$R^8 =$  acyl, then the other  $= H$  or alkyl;

$n = 0$  or  $2$ ;

$R^2 = H$ , alkyl, or acyl;

$R^3 = H$ , halo, or  $OR^9$ ; where  $R^9 = H$ , alkyl, or acyl;


---- = single or non-cumulated double bond, with the provisos that a *cis* double bond is present between carbons 4 and 5; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

$X = (CH_2)_m$  or  $(CH_2)_mO$ , where  $m = 1-6$ ; and

$Y =$  phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy; or



$X-Y = (CH_2)_p Y^1$ ; where  $p = 0-6$ ; and



wherein:

$W = CH_2, O, S(O)_q, NR^{10}, CH_2CH_2, CH=CH, CH_2O, CH_2S(O)_q, CH=N$ , or  $CH_2NR^9$ , where  $q = 0-2$ , and  $R^{10} = H$ , alkyl, or acyl;

$Z = H$ , alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or hydroxy; and

---- = single or double bond.

15. The compound of claim 14 wherein:

$R^1 = CO_2R$ ; where  $R = H$ ; or  $CO_2R$  = pharmaceutically acceptable ester moiety, where  
 $R = \text{alkyl}$ ;

$n = 0$ ;


$R^2 = H$ ;

$R^3 = OH$  in the alpha ( $\alpha$ ) configuration, or Cl or F in the beta ( $\beta$ ) configuration;


$X = CH_2O$ ; and

$Y = \text{phenyl}$ , optionally substituted with halo or trihalomethyl.

16. The compound of claim 15, having the formula:



17. An ophthalmic composition for the treatment of glaucoma and ocular hypertension, comprising a compound of formula I:



wherein:

$R^1 = CO_2R$ ,  $CONR^4R^5$ ,  $CH_2OR^6$ , or  $CH_2NR^7R^8$ ; where:

$R = H$  or cationic salt moiety, or  $CO_2R =$  ophthalmically acceptable ester moiety;

$R^4, R^5 =$  same or different  $= H$  or alkyl;  $R^6 = H$ , acyl, or alkyl;  $R^7, R^8 =$  same or different  $= H$ , acyl, or alkyl; with the proviso that if one of  $R^7, R^8 =$  acyl, then the other  $= H$  or alkyl;

$n = 0$  or  $2$

$R^2 = H$ , alkyl, or acyl;


$R^3 = H$ , halo, or  $OR^9$ ; where  $R^9 = H$ , alkyl, or acyl;

---- = single or non-cumulated double bond, with the provisos that if a double bond is present between carbons 4 and 5, it is of the *cis* configuration; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;

$X = (CH_2)_m$  or  $(CH_2)_mO$ , where  $m = 1-6$ ; and

$Y =$  phenyl, optionally substituted with alkyl, halo, trihalomethyl, alkoxy, acyl, acyloxy, amino, alkylamino, acylamino, or hydroxy; or

$X-Y = (CH_2)_p Y^1$ ; where  $p = 0-6$ ; and



wherein:

$W = CH_2, O, S(O)_q, NR^{10}, CH_2CH_2, CH=CH, CH_2O, CH_2S(O)_q, CH=N$ , or  $CH_2NR^9$ ,

where  $q = 0-2$ , and  $R^{10} = H$ , alkyl, or acyl;

$Z = H$ , alkyl, alkoxy, acyl, acyloxy, halo, trihalomethyl, amino, alkylamino, acylamino, or hydroxy; and

---- = single or double bond;

and an ophthalmically acceptable vehicle therefor.

18. The composition of claim 17 wherein:

$R^1 = CO_2R$ ; where  $R = H$ ; or  $CO_2R$  = ophthalmically acceptable ester moiety, where  $R = \text{alkyl}$ ;

$n = 0$ ;

$R^2 = H$ ;


$R^3 = OH$  in the alpha ( $\alpha$ ) configuration, or Cl or F in the beta ( $\beta$ ) configuration;

---- = single or non-cumulated double bond, with the provisos that if double bond is present between carbons 4 and 5 or carbons 5 and 6, it is of the *cis* configuration; and that if a double bond is present between carbons 13 and 14, it is of the *trans* configuration;


$X = CH_2O$ ; and

$Y = \text{phenyl}$ , optionally substituted with halo or trihalomethyl.


19. The composition of claim 18, wherein the compound is of the following formula:




20. The composition of claim 18, wherein the compound is of the following formula:




21. The composition of claim 18, wherein the compound is of the following formula:




22. The composition of claim 18, wherein the compound is of the following formula:



23. The composition of claim 18, wherein the compound is of the following formula:



24. The composition of claim 18, wherein the compound is of the following formula:



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/20856

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/557

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 008 775 A (FOX IRWIN) 9 May 1978 cited in the application see column 15, line 45-51 see column 16, line 35-47 see column 18, line 50-55 see column 19, line 22-35 see column 27, line 52-57 see column 28, line 1-49 see column 30, line 10-11 see column 30, line 38-40 see column 32; example 9 see column 35; example 10 see column 37; example 12 see column 40; example 17	14, 15, 17, 18
Y	see column 41, line 56-66 see column 42; example 19 --- -/-	8-13, 16, 19-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 February 1998

Date of mailing of the international search report

13. 03. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Trifilieff-Riolo, S



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20856

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 480 900 A (DESANTIS JR LOUIS ET AL) 2 January 1996 cited in the application see column 6, line 57 see column 7, line 12-13 see column 8, line 29-30 ---	1-7,14, 15,17,18
X	US 4 870 104 A (VORBRUGGEN HELMUT ET AL) 26 September 1989 cited in the application see column 12; example 6 ---	14,15, 17,18
Y	EP 0 580 268 A (UENO SEIYAKU OYO KENKYUJO KK) 26 January 1994 see page 13 - page 14; table 1 ---	8-13,16, 19-24
A	WOODWARD ET AL: "marked differential effects of prostanoid metabolites on rabbit intraocular pressure" OPHTHALMIC RESEARCH, vol. 21, no. 6, 1989, pages 428-435, XP002055464 see page 432, right-hand column see page 430; figure 1 -----	1-24

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 97/20856

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/20856

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1-13

because they relate to subject matter not required to be searched by this Authority, namely:

see remark

Remark : Although claims 1-13 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Patent Application No

PCT/US 97/20856

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4008775 A	22-02-77	CA 1047243 A DE 2431226 A GB 1471607 A JP 50070285 A	30-01-79 16-01-75 27-04-77 11-06-75
US 5480900 A	02-01-96	US 5605922 A AT 153855 T AU 674038 B AU 5328694 A DE 69311361 D DE 69311361 T EP 0664707 A JP 8502485 T WO 9408585 A	25-02-97 15-06-97 05-12-96 09-05-94 10-07-97 08-01-98 02-08-95 19-03-96 28-04-94
US 4870104 A	26-09-89	DE 3325175 A DE 3485436 A WO 8500367 A EP 0147461 A JP 6092362 B JP 60501813 T US 4983629 A	17-01-85 20-02-92 31-01-85 10-07-85 16-11-94 24-10-85 08-01-91
EP 0580268 A	26-01-94	JP 2008226 C JP 2096528 A JP 7039343 B JP 2009965 C JP 2096529 A JP 7039344 B AT 111736 T AT 162074 T DE 68918391 D DE 68918391 T EP 0366279 A US 5194429 A US 5236907 A	11-01-96 09-04-90 01-05-95 02-02-96 09-04-90 01-05-95 15-10-94 15-01-98 27-10-94 19-01-95 02-05-90 16-03-93 17-08-93